Influence of ketanserin (serotonin antagonist) on bladder and urethral function

doi:10.1016/0090-4295(87)90121-X

Urology

Volume 29, Issue 6, June 1987, Pages 669-673

https://doi.org/10.1016/0090-4295(87)90121-X Get rights and content

Abstract

As it is known that serotonin or 5-hydroxytryptamine can enhance bladder activity, we studied urodynamically the effect of ketanserin, a serotonin antagonist, in 17 patients, in the hope that this drug might be useful in treating unstable bladders. However, a relaxant effect on bladder contractility could not be demonstrated. On the contrary, a significant decrease of the urethral pressure was observed, suggesting that ketanserin might still have a possible role in promotion of bladder emptying. The relaxant effect on the urethra suggests some alpha-sympathicolytic activity of ketanserin.

References (15)

L.D. Cardozo et al.
A comparison between bromocriptine and indomethacin in the treatment of detrusor instability
J Urol
(1980)
O.P. Khanna et al.
Histamine receptors in urethrovesical smooth muscle
Urology
(1977)
O.P. Khanna et al.
Effects of prostaglandins on vesicourethral smooth muscle of rabbit
Urology
(1978)
S. Vaidyanathan et al.
Clinical import of serotonin activity in the bladder and urethra
J Urol
(1981)
D.J. Farrar et al.
The use of bromocriptine in the treatment of unstable bladder
Br J Urol
(1976)
K.P.J. Delaere et al.
Has bromocriptine a place in the treatment of the unstable bladder
Br J Urol
(1978)
Idem
The use of indomethacin in the treatment of idiopathic bladder instability
Urol Int
(1981)

There are more references available in the full text version of this article.

Cited by (8)

Pharmacological characterization of isolated human prostate
2003, Journal of Urology
Human prostate contains α-1 adrenergic, cholinergic and nonadrenergic noncholinergic neuroreceptors. Using agonistic and antagonistic agents at these neuroreceptors we studied the resultant contractile responses in isolated human prostate.
Human prostate tissue was obtained at prostatectomy for benign prostatic hyperplasia in 37 adult male patients. Tissues were suspended in tissue bath chambers connected to force displacement transducers. Specimens were subjected to agonist induced contractions, the first always being norepinephrine (NE). Specimens were pretreated with antagonist (adrenergic, cholinergic, nonadrenergic noncholinergic or none if control), followed by contraction with a second agonist (NE or other). Contractile tensions were recorded on a polygraph and then statistically analyzed.
The order of highest to lowest agonist induced tensile forces was NE, dopamine, acetylcholine, bethanechol, histamine and serotonin. Excitatory concentration EC₅₀ values were determined for each agonist tested. Significant differences were found between specific α-1 adrenergic receptor blockers (terazosin, prazosin and the experimental drug LY253352). In addition, many other agents antagonized the α-1 adrenergic receptor. Inhibitory concentration IC₅₀ values were obtained and the order of α-1 adrenergic antagonistic strengths from strongest to weakest was LY253352, prazosin, terazosin, ketanserin, SCH23390, diphenhydramine, DO710, dopamine, serotonin and histamine.
Human prostate neuroreceptors were determined to be α-1 adrenergic, dopaminergic, muscarinic cholinergic, 2A serotonergic and H1 histaminergic. Dopamine, serotonin, histamine and their antagonists blocked the adrenergic response, indicating possible receptor-receptor interaction. Further study of the pharmacology of human prostate would likely identify new drugs for treating patients with bladder outlet obstruction due to benign prostatic hyperplasia.
Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomised trials with 3283 deaths in 5710 patients
1995, The Lancet
Summary
A systematic overview, or meta-analysis, of the randomised evidence on maximum androgen blockade (MAB) in advanced prostate cancer identified 25 trials that compared conventional castration (surgical or medical) versus MAB (castration plus prolonged use of an anti-androgen such as flutamide, cyproterone acetate, or nilutamide).
Individual patient data were obtained from 22 of the trials. Median follow-up was 40 months, during which 57% of patients died (3283/5710). Crude mortality rates were 58% for castration alone and 56% for MAB. Life-table estimates of the corresponding 5-year survival rates were 22·8% and 26·2%, representing a non-significant improvement of 3·5% (95% Cl 0-7%). Logrank time-to-death analyses found no significant heterogeneity between trials (or between the effects of different types of MAB) and no significant evidence of additional benefit in an overview of all these MAB trial results (2p >0·1).
The currently available evidence from randomised trials does not show that MAB results in longer survival than conventional castration.
Canine, but not rat bladder contracts to serotonin via activation of 5HT<inf>2</inf> receptors
1990, Journal of Urology
Serotonin is a biogenic amine that can exert multiple effects on smooth muscle, including smooth muscle of the genitourinary tract; effects that may be species dependent. The present study using isolated tissues documents potent contractile responses to serotonin in canine bladder smooth muscle. Contractile responses to serotonin in canine bladder could be mimicked by a-methyl serotonin, a selective 5HT₂ receptor agonist. In fact, although a-methyl serotonin was slightly less potent as a contractile agonist relative to serotonin, the contractile response to a-methyl serotonin was more persistent as evidenced by a greater recovery time to resting force following washout. In contrast, the 5HT_1A receptor agonist, 8-OH-DPAT and the 5HT₃ selective agonist, 2-methyl serotonin, did not markedly contract canine bladder. These data establish that contractile responses to serotonin in the canine bladder are mediated by activation of 5HT₂ receptors. We further demonstrated that the 5HT₂ receptor antagonist, LY53857, potently inhibited the contractile response to both serotonin and a-methyl serotonin in the canine bladder consistent with agonist activation of 5HT₂ receptors. In contrast to the potent response to serotonin observed in the canine bladder, rat bladder preparations did not markedly contract in response to serotonin, α-methyl serotonin, 8-OH-DPAT, or 2-methyl serotonin. Thus, these studies reinforce the marked species variability in responsiveness to serotonin and indicate that contraction to serotonin in the canine bladder is mediated by activation of the 5HT₂ receptor. (J. Urol, 143: 1037–1040, 1990)
Pharmacology of the lower urinary tract: Basis for current and future treatments of urinary incontinence
2004, Pharmacological Reviews
Serotonin and serotonin antagonism in cardiovascular and non- cardiovascular disease
1995, Journal of Clinical Pharmacology
Evidence for an inhibitory 5‐HT<inf>4</inf> receptor in urinary bladder of Rhesus and Cynomolgus monkeys
1994, British Journal of Pharmacology

View all citing articles on Scopus

View full text

UrodynamicsInfluence of ketanserin (serotonin antagonist) on bladder and urethral function

Abstract

J Urol

Urology

Urology

J Urol

The use of bromocriptine in the treatment of unstable bladder

Br J Urol

Has bromocriptine a place in the treatment of the unstable bladder

Br J Urol

The use of indomethacin in the treatment of idiopathic bladder instability

Urol Int

Urodynamics
Influence of ketanserin (serotonin antagonist) on bladder and urethral function